Drug Profile
Trastuzumab biosimilar - Apobiologix
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Apobiologix
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Breast-cancer in USA (Parenteral)
- 10 Feb 2017 Preclinical trials in Breast cancer in USA (Parenteral)